Pharmaceutical company GlaxoSmithKline and inventor Triantafyllos Tafas have each petitioned the U.S. Court of Appeals for the Federal Circuit for an en banc rehearing of a March 20 decision that upheld the U.S. Patent and Trademark Office’s authority to issue three of four controversial patent rules.
The 2-1 majority opinion in Tafas v. Doll upheld rules that require a more cumbersome process for requesting continuing patent applications and other rules that sharply restrict the number of patent claims on an application unless the applicant files so-called examination support documents, which are expensive to produce.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
